Once medical insurance assigns a code and sets a price, an implantable medical technology has its ticket to enter. But as China News Service cautioned, insurance coding is only a "ticket" for market access, not an "insurance policy" for commercial success. With the ticket in hand, a string of more mundane questions lands in the daily work of hospitals and departments.
The report asks these questions one after another: will hospitals buy the equipment, will doctors dare to use it, and are patients suitable? None of the three is rhetorical; each is a checklist item needing a real answer. Whether a technology moves from paper to bedside often stalls not in the lab but over who procures, who operates and who handles the follow-up.
Making this layer clear matters more than repeating any reimbursement percentage. A ticket settles only the right to charge; for equipment to truly run in a hospital, someone must buy it, someone must know how to use it, and someone must maintain it over time. The gap in between is what the following pages take apart.
A Ticket Is Not an Insurance Policy
Take the word "ticket" apart first. According to China News Service, what insurance mainly covers is the implantation fee for the surgery, the stage where the device goes in. It gives hospitals a basis for charging and spares patients one hesitation, but it does not automatically assemble the whole service, much less carry the equipment into the department.
A model that can keep running is far longer than this one implantation. According to the same report, the full business model for a brain-computer interface also involves equipment cost, post-operative rehabilitation training, long-term maintenance and software upgrades. Implanting it is only the beginning; who follows up over the years and how that is charged still sit outside the catalog.
Added together, these are the accounts a hospital really has to weigh. How much budget a device takes, whether post-operative training fits into the rehabilitation department, and who pays for software upgrades are all absent from the implantation-fee column. A ticket governs getting through the door; the days afterward are lived one by one by the department itself.
Three Hard Tests That Cannot Be Skipped
The report's judgment is that whether an implantable technology is widely accepted rests on three hard tests: whether long-term safety holds up to verification, whether real-world efficacy is stable and reliable, and whether hospital-side operating and maintenance procedures are simple enough to work. None of the three is written in a price table, nor can a catalog answer it for them.
The first belongs to time. A device inside the body has to withstand years of work, and safety is not settled by a single inspection; it rests on records accumulated through follow-up visit after follow-up visit. Changes invisible in the short term tend to show themselves only over years, which is the most laborious part of clinical evidence.
The second and third are more like two sides of a coin. Efficacy has to hold steady in the real world, not just look good in a fully equipped operating room; procedures have to be simple enough that a department is willing to schedule them, or the technology stays in a handful of hospitals. Both point to the same word: whether it can become routine.
The Hospital Side Is Not Ready
Spread the three questions out and the first lands on money. In the words of the China News Service report, whether hospitals will buy the equipment is the unavoidable starting point. Equipment is a fixed asset: there must first be a budget, space and supporting staff before a first case is even thinkable. One more item in the catalog does not mean one more machine in the storeroom.
The second lands on people. Whether doctors dare to use it involves training, qualifications, handling complications and a written emergency plan. When a new technology enters a department, someone usually has to be sent to learn it and someone has to write the steps into routine before it can reach the elective surgery schedule. There is no shortcut here, only practicing unfamiliar moves until they are familiar.
The third lands on fit. Whether a patient is suitable is assessed case by case by a doctor, weighing age, course of disease, underlying conditions and expected benefit. According to China News Service, not everyone is suited to a brain-computer interface. Reading access as meaning anyone can have it is the easiest misunderstanding to slip into.
The Account According to a Company Executive
On costs, there is an account from the company side. According to an interview CNR conducted at the annual Zhongguancun Forum, Hao Hongwei, general manager of Beijing Pins Medical Co., Ltd. and deputy director of the National Engineering Research Center for Neuromodulation, spoke about the rough expense of the two kinds of treatment.
According to the company executive, implant surgery ranges from tens of thousands of yuan to two or three hundred thousand yuan depending on the product and complexity; non-invasive rehabilitation training is charged by course, with a single session costing a few hundred yuan and a full course a few thousand. These are the ranges he gave, not a uniform price, and the actual figure still depends on the product and the course.
He also spoke about reimbursement. According to the company executive, when its implantable neuromodulation brain-computer interface devices are used for conditions such as Parkinson's disease and epilepsy, most provinces in the country have included them in medical insurance; in Beijing and Shanghai, for example, employee medical insurance can reimburse up to 80 percent. This is the executive's own account, not an official statistic.
That 80 percent especially needs to be kept in place. It refers to employee medical insurance in Beijing and Shanghai and comes from the company executive; compared with other reimbursement percentages seen elsewhere, the region, the insurance type and whether consumables or the entire operation is being counted all differ, so they do not belong side by side in a comparison. Every number has its own ledger.
Tests and Rehabilitation Fill Their Places
Beyond the ticket, the two ends are slowly being filled in. According to reports by Jingchu Net and Changjiang Yun News, Hubei set billing rules for near-infrared brain functional imaging as part of the full treatment process, giving pre-operative assessment something to rely on and avoiding a test being done with no item to bill it under.
The post-operative end has its rules too. The same report states that patients who have had brain-computer interface surgery or treatment may use brain-computer interactive smart devices for specific assessments and functional rehabilitation training, charged on top of existing rehabilitation main items, add-on items and extension items according to the technical difficulty of post-operative brain-computer rehabilitation.
Only by laying out the charges for tests, implantation and rehabilitation together can one see how many boxes remain behind a single ticket. Price items settle whether a bill can be issued; the charges for tests and rehabilitation settle whether the two ends have a basis. But who buys the equipment, who trains the doctors and who screens the patients remain three questions the hospital must answer itself.
For an ordinary reader, when judging news that a technology has entered medical insurance, it helps to go one step further along this line: a code exists, but where is the equipment; an item exists, but who performs it; a percentage exists, but which part of the cost does it count. Only when those three land does a technology truly step out of the documents and settle steadily at the bedside.
A ticket placed in one's hand is a real good thing, but it only says the door is open. Whether the equipment has come in, whether doctors have practiced enough, whether patients are screened properly, and who maintains everything over the years are mundane questions written in no price table, yet they decide whether anyone keeps coming through that door. Filling in these links is more worth waiting for than one more number.
Disclaimer: This article is based on publicly available information and is for reference only. It does not constitute investment advice.